Vertex partners with basketball world champion jayson tatum to raise awareness of journavx®, a non-opioid medicine approved for the treatment of moderate-to-severe-acute pain

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that the company has partnered with basketball world champion jayson tatum to raise awareness of journavx® (suzetrigine), a prescription non-opioid medicine for the treatment of moderate-to-severe acute pain in adults and the first new class of pain medicine approved in more than 20 years. during the 2025 playoffs in may, jayson ruptured his achilles tendon, a season-ending injury that required immediate.
VRTX Ratings Summary
VRTX Quant Ranking